Elicio Therapeutics (ELTX) Non Operating Income (2020 - 2026)
Elicio Therapeutics posted quarterly Non Operating Income of -$1.2 million for Q1 2026, down 158.14% year-on-year from $2.1 million in Q1 2025, and down 208.63% on a QoQ basis from $1.1 million in Q4 2025.
Elicio Therapeutics (ELTX) has 7 years of Non Operating Income data on file, last reported at -$1.2 million in Q1 2026.
- For the quarter ending Q1 2026, Non Operating Income fell 158.14% year-over-year to -$1.2 million; the trailing twelve-month figure through Mar 2026 stood at -$2.6 million (up 55.09% YoY), and the FY2025 full-year result was -$1.9 million, up 73.13% from the prior year.
- Non Operating Income for Q1 2026 stood at -$1.2 million, down from $1.1 million in the prior quarter.
- Across five years, Non Operating Income topped out at $3.7 million in Q2 2024 and bottomed at -$8.5 million in Q3 2024.
- The 5-year median for Non Operating Income is -$473000.0 (2025), against an average of -$728294.1.
- Peak annual rise in Non Operating Income reached 1594.95% in 2024, while the deepest fall reached 7616.81% in 2024.
- A 5-year view of Non Operating Income shows it stood at -$690000.0 in 2022, then soared by 164.2% to $443000.0 in 2023, then plunged by 219.19% to -$528000.0 in 2024, then jumped by 312.88% to $1.1 million in 2025, then slumped by 208.63% to -$1.2 million in 2026.
- The last three Non Operating Income figures came in at -$1.2 million (Q1 2026), $1.1 million (Q4 2025), and -$2.0 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 444,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 201.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -46.98 Mn |
| 10 | Elicio Therapeutics | 217.63 Mn | 202.68 Mn | - | -1.22 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.22 Mn |
| Dec 31, 2025 | 1.12 Mn |
| Sep 30, 2025 | -2.04 Mn |
| Jun 30, 2025 | -470,000.00 |
| Mar 31, 2025 | -473,000.00 |
| Dec 31, 2024 | -528,000.00 |
| Sep 30, 2024 | -8.49 Mn |
| Jun 30, 2024 | 3.70 Mn |
| Mar 31, 2024 | -1.59 Mn |
| Dec 31, 2023 | 443,000.00 |
| Sep 30, 2023 | 113,000.00 |
| Jun 30, 2023 | 218,000.00 |
| Mar 31, 2023 | -224,000.00 |
| Dec 31, 2022 | -690,000.00 |
| Sep 30, 2022 | -1.43 Mn |
| Jun 30, 2022 | -1.07 Mn |
| Mar 31, 2022 | 245,000.00 |
| Dec 31, 2021 | 256,000.00 |
| Sep 30, 2021 | 54,000.00 |
| Jun 30, 2021 | 1.17 Mn |
| Mar 31, 2021 | -16.75 Mn |
| Dec 31, 2020 | -15.03 Mn |
| Sep 30, 2020 | -6.08 Mn |
| Jun 30, 2020 | -3.07 Mn |
| Mar 31, 2020 | -653,000.00 |